Bullish View on Spruce Biosciences; Kroger Posts Mixed Results
- September 08th, 2023
- 421 views
Spruce Biosciences, Inc. (Nasdaq: SPRB), a pharmaceutical company, was upgraded from Market Perform to Outperform by SVB Leerink, accompanied by a revised price target increase from $3 to $9.
Given that $SPRB closed at $2.23 on Thursday, this adjusted price target suggests a potential upside of $6.77 per share or approximately 303.13%, based on the assessment by the investment firm.
In other news, The Kroger Co. (NYSE: KR), a major retail corporation, reported second-quarter 2023 earnings of $0.96 per share, surpassing the consensus EPS estimate of $0.91. The company's quarterly sales amounted to $33.85 billion, slightly below analysts' projected revenue of $34.13 billion for the period.
$KR was trading at $44.54 in pre-market, down $0.99 (-2.17%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login